Investigating the serum level of prohibitin I and its relationship with prognostic factors in breast cancer

سال انتشار: 1394
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 413

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

این مقاله در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

ICBCMED12_187

تاریخ نمایه سازی: 2 تیر 1397

چکیده مقاله:

Background &Aim: Breast cancer is the most common cancer among women in the world. Prohibitin (PHB) is a homologous protein which binds to P53 protein and enhances its transcriptional activity. It has been also reported that PHB1 may act as an anchor in the cell membrane for C-Raf. The aim of this study was to measure the level of PHB1 in serum of patients with breast cancer. Methods: Blood samples were taken from 78 patients who had referred to Omid University-Hospital in Mashhad and were willing to participate in the study. After obtaining informed consent, the serum level of prohibitin was measured in collected sera by ELISA method using Kazabayo Company research kit according to the protocol provided. The relationship between the serum level of PHB1 and other known prognostic factors of breast cancer was investigated Results: Prohibitin level in serum of patients was reported with a median of 1.03 ng/ml. A slight increase in the level of PHB1 was seen with higher tumoral grade, and also in people with positive ER (estrogen receptor) and PR (progesterone receptor) compared to people with negative hormone receptors; but no significant correlation with these factors neither other factors (including HER2) was detected. Conclusion: Our study did not show any significant correlation between serumic level of PHB1 and tumor stage; though, in previous reports tissue distribution of prohibitin have shown a good correlation with prognostic factors in breast cancer using immunohistochemistry technique. This might be due to insufficient level of PHB in the blood

کلیدواژه ها:

نویسندگان

Hossein Javid

Department of Clinical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IRAN

Seyyed Isaac Hashemy

Department of Clinical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IRAN

Soudabeh shahidsales

Department of Oncology, Omid Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Nema Mohammadian Roshan

Department of Pathology, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran